MECHANISMS OF RESISTANCE TO IMMUNOLOGICAL TARGETING OF PRIMARY AND METASTATIC COLORECTAL CANCERS
Grant number: 1140147 | Funding period: 2018 - 2021
The immune system influences the outcome in patients with cancer. We have been early adopters of immunotherapy approaches to target cancer cells using the novel approaches to enhance immune attack on cells that aberrantly express cancer regulators. These represent drivers to which cancer cells are addicted. A central tenant of optimizing immunotherapies has been to employ immune stimuli in concert with removing immune blocking systems. Our research plan is to improve immunotherapy efficiency.
Related publications (2)
First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)
Toan Pham, Lloyd Pereira, Sara Roth, Laura Galletta, Emma Link, Tim Akhurst, Ben Solomon, Michael Michael, Phillip Darcy, Shienny Sampurno, Alexander Heriot, Robert Ramsay, Jayesh Desai
Background: MYB is a transcription factor that is overexpressed in colorectal cancer (CRC) and also a driver mutation in adenoid c..
Modeling open surgery in mice to explore peritoneal damage, carbon dioxide humidification and desmoidogenesis
Timothy Chittleborough, Shienny Sampurno, Sandra Carpinteri, Andrew Craig Lynch, Alexander Graham Heriot, Robert George Ramsay
<jats:title>Abstract</jats:title> <jats:sec id="j_pp-2019-0023_s_001a"> <jats:title id="d238055e10498">Background</jats:title> <ja..